Kyverna Therapeutics Announces Positive Interim Phase 2 Data for KYV-101 in Generalized Myasthenia Gravis

Kyverna Therapeutics, Inc. reported positive interim data from the Phase 2 portion of its KYSA-6 Phase 2/3 trial of KYV-101 in generalized myasthenia gravis (gMG). The data showed robust, rapid, and sustained reductions in disease activity scores, with 100% of patients achieving clinically meaningful responses. The treatment was well-tolerated, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed. The company plans to host a conference call to review the results and has furnished a copy of the presentation slides as an exhibit to the Form 8-K. The data supports the potential of KYV-101 to change the treatment paradigm in gMG, with a Phase 3 trial expected to begin by the end of 2025.